Design and synthesis of novel cytotoxic fluoroquinolone analogs through topoisomerase inhibition, cell cycle arrest, and apoptosis

Abstract

Abstract To exploit the advantageous properties of approved drugs to hasten anticancer drug discovery, we designed and synthesized a series of fluoroquinolone (FQ) analogs via functionalization of the acid hydrazides of moxifloxacin, ofloxacin, and ciprofloxacin. Under the NCI-60 Human Tumor Cell Line Screening Assay, ( IIIf ) was the most potent among moxifloxacin derivatives, whereas ( VIb ) was the only ofloxacin derivative with significant effects and ciprofloxacin derivatives were devoid of activity. ( IIIf ) and ( VIb ) were further selected for five-dose evaluation, where they showed potent growth inhibition with a mean GI 50 of 1.78 and 1.45 µM, respectively. ( VIb ) elicited a more potent effect reaching sub-micromolar level on many cell lines, including MDA-MB-468 and MCF-7 breast cancer cell lines (GI 50 = 0.41 and 0.42 µM, respectively), NSCLC cell line HOP-92 (GI 50 = 0.50 µM) and CNS cell lines SNB-19 and U-251 (GI 50 = 0.51 and 0.61 µM, respectively). ( IIIf ) and ( VIb ) arrested MCF-7 cells at G1/S and G1, respectively, and induced apoptosis mainly through the intrinsic pathway as shown by the increased ratio of Bax/Bcl-2 and caspase-9 with a lesser activation of the extrinsic pathway through caspase-8. Both compounds inhibited topoisomerase (Topo) with preferential activity on type II over type I and ( VIb ) was marginally more potent than ( IIIf ). Docking study suggests that ( IIIf ) and ( VIb ) bind differently to Topo II compared to etoposide. ( IIIf ) and ( VIb ) possess high potential for oral absorption, low CNS permeability and low binding to plasma proteins as suggested by in silico ADME calculations. Collectively, ( IIIf ) and ( VIb ) represent excellent lead molecules for the development of cytotoxic agents from quinolone scaffolds.